Press releases
Company

Press releases

Genomatix to partner in €30M European epigenomics consortium.

Genomatix will provide data analysis and develop visualization interfaces for the recently started BLUEPRINT project.

 

München, Germany, 17 October 2011 - Genomatix is among the 41 partners of the BLUEPRINT epigenome consortium funded by the European Commission as a high impact project within its seventh framework program (FP7).

 

Genomatix' contributions will be next generation sequencing data analysis and the development of an intuitive GUI to make the project's results easily accessible to researchers within and outside the consortium.

 

"To be part of, and get substantial funding of this ambitious project, is a pleasant affirmation of our research and development efforts to provide high quality data analysis in a very usable way for biologists", says Dr. Martin Seifert, CEO of Genomatix. "We highly appreciate the European Commission's commitment to support SMEs in its current FP7 program, as it enables us to participate in a high-profile research project that will generate fascinating new insights into epigenomics. It is of direct relevance to our business, as it will help us to offer our customers an even broader biological data background for their research. This will improve the understanding of molecular processes and hence lead to better biomedical applications."

 

Dr. Korbinian Grote, product manager at Genomatix, adds: "The BLUEPRINT epigenome project is a chance to work with high-quality epigenomics data from renowned institutions and labs from all over Europe. It will help us to further improve our existing line of next generation sequencing analysis products and will lead to the implementation of new ideas tailored towards the integration of epigenomic data into our interfaces and visualizations."

 

About BLUEPRINT:
In response to the call for a High Impact Initiative on the human epigenome, the BLUEPRINT consortium has been formed with the aim of generating at least 100 reference epigenomes and studying them to advance and exploit knowledge of the underlying biological processes and mechanisms in health and disease. BLUEPRINT will focus on distinct types of haematopoietic cells from healthy individuals and on their malignant leukaemic counterparts. Reference epigenomes will be generated by state-of-the-art technologies from highly purified cells for a comprehensive set of epigenetic marks in accordance with quality standards set by the International Human Epigenome Consortium (IHEC). The BLUEPRINT project has a total budget of almost 40 million euro and will receive 30 million euro funding from the EC-FP7-Cooperation-Health budget. The project started on October 1, 2011 and will run for 4.5 years. For further information, please visit http://www.blueprint-epigenome.eu/

 

About Genomatix:
Genomatix Software GmbH is one of the world's leading suppliers of technologies to analyze and interpret genomic data. Headquartered in Munich (Germany), Genomatix has a global presence by representations in Ann Arbor, MI (USA), Paris (France), London (UK) and Tokyo (Japan). Founded in 1997, Genomatix pioneered the analysis and understanding of eukaryotic gene regulation. More than a decade of developments in computational and systems biology has put Genomatix into the position to have all needed data content and a complete analysis pipeline in place at the arrival of next generation sequencing technology. Genomatix has published more than 120 peer reviewed scientific papers with more than 5,000 citations. Over 35,000 researchers worldwide currently apply Genomatix tools and databases. For further information, please visit http://www.genomatix.com

 

For further information please contact:

Genomatix
Dr. Martin Seifert
Email: seifert@genomatix.de
Phone: +49 89 599 766 0

Genomatix wins "Most Creative VIsualization" award at iDEA Challenge 2011.

Genomatix' solutions for NGS data analysis awarded in the commercial category at Illumina's San Diego iDEA conference.

 

Munich, Germany, August 23, 2011 - Genomatix has recently won the "Most Creative Visualization" award in the "commercial" category of Illumina's Data Excellence (iDEA) Challenge 2011, an achievement we are extremely proud of. iDEA is Illumina's program designed to challenge the scientific community to develop new and creative visualization and data analysis techniques.

 

"The iDEA challenge really sparked our interest from the very first moment we heard about it. Genomatix is a scientific company at heart, and we felt that getting our hands on a high quality, widely diverse dataset like the one Illumina provided for the Challenge would be an ideal test for our scientific approach to data analysis... which is to combine multiple lines of evidence to get from sequencing data to biological knowledge" says Dr. Jochen Supper, who presented Genomatix' submission at the San Diego iDEA meeting.

 

Dr. Martin Seifert, CEO of Genomatix, adds: "The Challenge was judged by a panel of renowned experts from the scientific community, and this is a great endorsement of the work we've done to date, as well as a significant motivation to push even harder in the future. Genomatix has always focused on providing intuitive interfaces and easy-to-understand visualizations. The combination of our scientifically validated algorithms and wealth of annotation data allows us to offer a comprehensive platform solution for Next Generation Sequencing data analysis. With the iDEA data being generated from cancer cell lines it also underlines the increasing relevance of our technologies for medical applications."

 

Additional coverage on the iDEA challenge can be found at Illumina's webpage (http://www.illumina.com/landing/idea/index.ilmn), Illumina's iCommunity newsletter (http://www.illumina.com/emailers/20110622_icommunity_june/iCommunity_june_2011_index_web.html) or the July/August issue of Bio-IT World magazine (http://www.bio-itworld.com). The finalists' presentations are available at http://www.illumina.com/landing/idea/conference/finalists.ilmn.


About Genomatix:

Genomatix Software GmbH is one of the world's leading suppliers of technologies to analyze and interpret genomic data. Headquartered in Munich (Germany), Genomatix has a global presence by representations in Ann Arbor, MI (U.S.A), Paris (France), London (U.K.) and Tokyo (Japan). Founded in 1997, Genomatix pioneered the analysis and understanding of eukaryotic gene regulation. More than a decade of developments in computational and systems biology has put Genomatix into the position to have all needed data content and a complete analysis pipeline in place at the arrival of next generation sequencing technology. Genomatix has published more than 120 peer reviewed scientific papers with more than 5,000 citations. Over 35,000 researchers worldwide currently apply Genomatix tools and databases. For further information, please visit http://www.genomatix.de or http://www.mygenomatix.com.

Genomatix Software, USU, and HJF Execute a CRADA: Prostate Cancer Prognostic Marker Discovery by Next Generation Sequencing

Cooperation to further progress in prostate disease research.


Munich, Germany, August 22, 2011 - Genomatix Software, the Uniformed Service University of the Health Sciences (USU), and the Henry M. Jackson Foundation (HJF) for the Advancement of Military Medicine, Inc. have entered into a Cooperative Research and Development Agreement (CRADA) to extend their collaborative endeavors in prostate disease research. The aim of the joint research will be to differentiate patients with favorable versus poor prognosis at the time of diagnosis and primary treatment using definitive genetic markers. The majority of prostate cancer cases in PSA-screened population fall into a so called "grey zone" of prostate cancer where outcome is extremely difficult to predict at the time of diagnosis. The CRADA extends a long and already fruitful collaboration (Masuda, Werner et al, J Mol Biol. 353, 763-771 2005; Furusato et al, PCPD. 11, 194-97, 2008) with USU's Center for Prostrate Disease Research (CPDR). This collaboration combines CPDR's translational research resources and expertise and Genomatix' data analysis expertise in teasing out novel androgen receptor binding sites in the genome and analyzing prostate cancer metastasis using prostate cancer model systems and clinical specimens.

 

"This CRADA is a natural extension of accomplishments we have already achieved together," said Dr. Thomas Werner, founder of Genomatix Software. "Next Generation Sequencing opens a new dimension in biomarker research and will allow a finer grained, unbiased look at some of the genomic mechanisms behind prostate disease, thus providing the opportunity for the discovery of new prognostic biomarkers, some of which also may be targets for therapeutic intervention and treatment monitoring."

 

Dr. Shiv Srivastava; CPDR Co-director, Scientific Director, and Professor of Surgery at USU added: "Our work to date with Genomatix has been very productive. People from both our organizations have already established quality working relationships. Leveraging this and moving forward together into a technology as ground breaking as Next Generation Sequencing holds great promise for significant progress in prostate disease research."


About Genomatix:

Genomatix is one of the world's leading suppliers of technologies to analyze and interpret genomic data. As well as laying the groundwork for microarray experiments and NGS data analyses, our hardware and software solutions help answer the typical questions posed by systems biology. Our approach: combine multiple lines of evidence to perform an integrated meta-analysis.


About CPDR:

The Center for Prostate Disease Research is an internationally recognized interdisciplinary program of the Uniformed Services University of the Health Sciences (USU). USU is the nation's federal health sciences university. USU students are primarily active-duty uniformed officers in the Army, Navy, Air Force and Public Health Service who are being educated to deal with wartime casualties, emerging infectious diseases and other public health emergencies. CPDR is affiliated with the Walter Reed Army Medical Center (WRAMC), several other military medical centers, and the Joint Pathology Center (part of the recently disestablished Armed Forces Institute of Pathology), and is operated in collaboration with The Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc., a non-profit foundation chartered to support USU and military medicine. The CPDR's mission of integrating basic science and clinical research to develop promising detection techniques and treatments for prostate cancer and associated diseases is fulfilled primarily through its three principal programs - the Clinical Research Program at WRAMC, the Basic Science Research Program at USU, and the Multicenter National Prostate Cancer Database.

mygenomatix: A Secure Cloud Like Model for NextGen Sequencing Data Analysis

Genomatix Launches Analysis Service: Affordable AND Powerful

 

Munich, Germany, March 15 2011 - The growing amount of data created by today's high throughput DNA sequencing technology presents a major challenge to scientists around the globe. How to handle the staggering amount of data, and, more importantly, how to answer the biological questions that initiated the experiment? Aside from the cost of the sequencing platforms themselves, significant amounts of money are being spent worldwide to expand hardware and storage resources, but getting to the biology requires access to data bases, analysis pipelines and other technologies to convert the data into biological knowledge... a daunting requirement for many users of Next Generation Sequencing (NGS).

 

Genomatix has established itself as a pioneer in the field of NGS data analysis, and has marketed a leading edge data analysis platform for intranet, in-house use for several years. However, the investment required for this platform is often beyond the means of the occasional user or even small core facility, confining the beneficiaries of this leading technology to larger sequencing core facilities and heavy users of the technology.

 

At the San Diego X-Gen conference and at the Human Genome Meeting in Dubai, Genomatix announces now a new service: mygenomatix.

With mygenomatix, Genomatix launches a service model that incorporates all the power of its in-house platform and combines it with the affordability of cloud computing and the security of an in-house solution... all at a very affordable price. mygenomatix will provide the user with:

  • Speed: receive your analyzed data back in a matter of one to two weeks.
  • Quality: users of mygenomatix will have access to the full Genomatix software and background data content as part of the service.
  • Results: biology matters, and Genomatix has excelled in providing meaningful biological analyses for over 13 years. Get biological results instead of endless columns of numbers.
  • Security: unlike standard cloud models, your data is always in a secure, protected environment.
  • Ease: Genomatix software has an excellent graphical user interface and standard operating procedures and workflows, with our excellent support team available to help if needed.
  • Accessibility: access to the Genomatix software and data content is provided via any standard internet browser from any internet-connected computer.
  • Affordability: contact Genomatix to find out how surprisingly affordable mygenomatix is.

mygenomatix will accept raw sequence or color space NGS data or, depending on your preference, aligned data to leverage Genomatix' extensive analysis capabilities and deep annotation.

 

"We are happy to announce the start of www.mygenomatix.com", says Dr. Martin Seifert (CEO of Genomatix). "We want to provide an easy entry to our excellent NGS data analysis and interpretation capabilities, complementing our turn-key in-house platforms, the Genomatix Mining Station (GMS) and the Genomatix Genome Analyzer (GGA). We have been exploring a cloud like model for quite some time, and our service model addresses the issue of security by getting the data to our computers via a hard disk shipment program. With mygenomatix, anyone doing NGS data analysis now has access to an easy entry path to our technology and databases." The service will be launched in April.

 

About Genomatix:

Genomatix Software GmbH is one of the world's leading suppliers of technologies to analyze and interpret genomic data. Headquartered in Munich (Germany), Genomatix has a global presence by representations in Ann Arbor, MI (U.S.A), Paris (France), London (U.K.) and Tokyo (Japan). Founded in 1997, Genomatix pioneered the analysis and understanding of eukaryotic gene regulation. More than a decade of developments in computational and systems biology has put Genomatix into the position to have all needed data content and a complete analysis pipeline in place at the arrival of next generation sequencing technology. Genomatix has published more than 120 peer reviewed scientific papers with more than 5,000 citations. Over 35,000 researchers worldwide currently apply Genomatix tools and databases. For further information, please visit http://www.genomatix.de or http://www.mygenomatix.com.